Related coverage linked through entity extraction aliases.
Feb 23, 2026
An international research team has conducted the first comprehensive genetic study of cancer in domestic cats, identifying genetic changes that closely resemble those in human cancers and opening new perspectives for targeted therapies.
Feb 23, 2026
Two clinical trials demonstrate efficacy of talimogene laherparepvec (T-VEC) oncolytic virus therapy in HER2-negative breast cancer and nonmelanoma skin cancers, with favorable safety profiles and durable responses in subset of patients.
Feb 17, 2026
New clinical trial data show trastuzumab deruxtecan plus pertuzumab extends progression-free survival as first-line therapy, while MRI-guided treatment shortening reduces toxicity in neoadjuvant settings for HER2-positive breast cancer.
Feb 19, 2026
Moderna and Merck have begun recruiting for a Phase 2 trial testing V940, an mRNA-based personalized cancer vaccine, combined with Keytruda and chemotherapy as first-line treatment for metastatic squamous non-small cell lung cancer.
Feb 17, 2026
A UCLA study found that adding immunotherapy to chemotherapy before surgery is safe for borderline-resectable pancreatic cancer patients, with a subset experiencing complete tumor regression despite no overall survival advantage.
Feb 20, 2026
The FDA has accepted Roche's New Drug Application for giredestrant plus everolimus to treat ESR1-mutated, ER-positive advanced breast cancer, with a decision expected by December 18, 2026. The filing is based on phase III data showing significant reductions in disease progression risk.
Feb 20, 2026
The FDA has accepted a new drug application for giredestrant plus everolimus for ESR1-mutated, ER-positive, HER2-negative advanced breast cancer, with a decision expected by December 18, 2026. The phase 3 evERA study showed a 62% reduction in disease progression or death risk in ESR1-mutated patients.
Feb 20, 2026
A study published in Science sequenced cancer-related genes in 493 cat tumor samples across 13 cancer types, revealing striking genetic similarities with human cancers and opening possibilities for shared treatments.
Feb 19, 2026
AstraZeneca has completed a Phase IIb heart failure trial for AZD5462, finished a real-world breast cancer study in Brazil, and is recruiting for an observational COPD study in heart clinic patients.
Feb 18, 2026
Flatiron Health announced its first Panoramic datasets for prostate cancer patients in the UK and Germany, encompassing records of nearly 400,000 patients across three countries. The datasets leverage AI and large language models to provide unified real-world evidence for cancer research.
Feb 19, 2026
The global oncology market is projected to grow from $280 billion in 2026 to $748 billion by 2035 at 11.54% CAGR, driven by rising cancer incidence, precision medicine expansion, and strong immunotherapy pipelines across multiple tumor types.
Feb 18, 2026
Researchers at Case Western Reserve University developed a method using ultrasound-activated nanobubbles to break down the collagen barriers surrounding solid tumors, enabling better drug delivery and immune cell penetration. The therapy could reach clinical trials within two years.
Feb 18, 2026
Researchers develop machine-learned biomarker predicting liver cancer risk with 93% accuracy, while AI-driven drug repurposing offers faster, cost-effective alternatives to address cancer survivorship gaps.
Feb 18, 2026
A UCLA clinical trial found that adding immunotherapy to chemotherapy before surgery is safe for borderline-resectable pancreatic cancer patients, with a subset experiencing deep, durable responses including complete tumor regression.
Feb 17, 2026
New research identifies circulating tumor-reactive T cell characteristics and inflammatory biomarkers as predictive indicators for immune checkpoint inhibitor response in cancer patients, while the PD-L1 testing market is projected to reach $36.44 billion by 2032.
Feb 16, 2026
Artificial intelligence is advancing cancer care through early detection tools and improved clinical trial predictions. A Carnegie Mellon spinout is developing AI to identify high-risk patients, while predictive analytics are helping pharmaceutical companies prioritize promising compounds in oncology trials.
Feb 15, 2026
Recent research explores plant-based diets' association with breast cancer risk, disparities in care for Black women in Canada, and survival outcomes for young women with breast cancer in Latin America.
Feb 14, 2026
Researchers have developed modified CAR T cells that overcome prostaglandin E2 suppression in solid tumors and a selective therapy targeting IGHV4-34 that spares healthy immune cells, addressing key limitations in current treatments.
Feb 13, 2026
Immunotherapy is increasingly being used before and after surgery across seven cancer types, while the global immunotherapy drugs market experiences significant growth driven by advances in biotechnology and targeted therapies.
Feb 13, 2026
The FDA removed black box warnings related to breast cancer, cardiovascular disease and dementia from six hormone replacement therapies for menopausal women, following a comprehensive review of scientific literature.
